本帖最后由 老马 于 2013-3-13 13:43 编辑
6 C4 `; ]$ k. y2 j* p1 c, Z% F- L! \
健择(吉西他滨)+顺铂+阿瓦斯汀
+ C; d4 \# a/ i$ B' h: e$ E Gemzar +Cisplatin + Avastin
7 s( y3 y& p" A; r! B" B' ^http://annonc.oxfordjournals.org/content/21/9/1804.full
]0 J- t+ l1 C9 O$ h# iOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* P% }5 @; f. I3 a& EPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ _' o7 u3 F) D- g$ S" `# a, x! r* ~1 lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 3 M( `* ^! c, m! U8 M1 q @
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 898)
$ d; G- {& N$ |# `" h- W华为网盘附件:5 D6 d7 a$ a/ I5 i) P. q
【华为网盘】ava.JPG% _- z1 U' X8 K$ {. `% k
|